Curocell
The company is committed to developing innovative technologies to improve the efficacy of cancer treatments and address the limitations of traditional cancer immunotherapy drugs.
Launch date
Employees
Market cap
-
Enterprise valuation
€110—165m (Dealroom.co estimates Jan 2022.)
Company register number 1488800557
South Korea (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | N/A | - | |
* | N/A | - | |
N/A | Series C | ||
KRW36.0b | Late VC | ||
| Total Funding | €27.4m | ||